Primary Presacral Neuroendocrine Tumors Presented by Lumbosacral Pain: a Case Report
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2329
Abstract
Primary presacral neuroendocrine tumors (NETs) are exceedingly rare and often present with extensive metastases, posing significant challenges for clinical management. We report a case of a presacral neuroendocrine tumor in a 68-year-old male who presented with lumbosacral pain. Enhanced MRI revealed a soft tissue mass at the sacrococcygeal region, while whole-body enhanced 18F-PET/CT identified small intratumoral vessels and involvement of the adjacent rectal posterior wall, mesorectal fascia, presacral fascia, and sacrococcygeal bones, accompanied by multiple lymph node metastases and widespread metastases to the lungs, liver, and bones. A CT-guided biopsy confirmed the diagnosis of a grade 2 (G2) neuroendocrine tumor. Given the tumor's extensive metastasis and aggressive nature, surgical intervention was deemed unsuitable, and the patient was treated with sulfatinib. Sulfatinib shows significant potential in managing advanced neuroendocrine tumors, providing an effective therapeutic option for patients with such complex and high-risk conditions.
Keywords
neuroendocrine tumors, diagnostic imaging, presacral tumors
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] K. Öberg, and D. Castellano, Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer and Metastasis Reviews 30 (2011) 3-7.
[2] S. La Rosa, L. Boni, G. Finzi, D. Vigetti, N. Papanikolaou, S.M. Tenconi, G. Dionigi, M. Clerici, S. Garancini, and C. Capella, Ghrelin-Producing Well-Differentiated Neuroendocrine Tumor (Carcinoid) of Tailgut Cyst. Morphological, Immunohistochemical, Ultrastructural, and RT-PCR Study of a Case and Review of the Literature. Endocrine Pathology 21 (2010) 190-198.
[3] A. Lee, T.S. Suhardja, T.C. Nguyen, and W.M.-K. Teoh, Neuroendocrine tumour developing within a long-standing tailgut cyst: case report and review of the literature. Clinical Journal of Gastroenterology 12 (2019) 539-551.
[4] Z. Li, and M. Lu, Presacral Tumor: Insights From a Decade’s Experience of This Rare and Diverse Disease. Frontiers in Oncology 11 (2021).
[5] J. Ghosh, T. Eglinton, F.A. Frizelle, and A.J.M. Watson, Presacral tumours in adults. The Surgeon 5 (2007) 31-38.
[6] E. Canelles, J.V. Roig, M. Cantos, J. García Armengol, E. Barreiro, F.L. Villalba, M.D. Ruiz, and V. Pla, Tumores presacros. Análisis de nuestra experiencia en 20 casos tratados quirúrgicamente. Cirugía Española 85 (2009) 371-377.
[7] K. Kodera, S. Eto, N. Fukasawa, W. Kai, T. Matsumoto, T. Hirabayashi, H. Kawahara, and N. Omura, Laparoscopic resection of a neuroendocrine tumor that almost fully replaced tailgut cysts: a case report. Surgical Case Reports 6 (2020).
[8] D. Shi, G.-Q. Dong, K.-R. Shen, Y. Pan, S.-M. Wei, Y. Chen, and R.-S. Yu, Primary cystic and solid neuroendocrine tumor of the retroperitoneum. Medicine 100 (2021).
[9] V. Ulici, and J. Hart, Chordoma. Archives of Pathology & Laboratory Medicine 146 (2022) 386-395.
[10] E. Dekker, P.J. Tanis, J.L.A. Vleugels, P.M. Kasi, and M.B. Wallace, Colorectal cancer. The Lancet 394 (2019) 1467-1480.
[11] R. Syed, J.A. Bishop, and S.Z. Ali, Sacral and presacral lesions: Cytopathologic analysis and clinical correlates. Diagnostic Cytopathology 40 (2010) 7-13.
[12] Ashley K. Clift, M. Kidd, L. Bodei, C. Toumpanakis, Richard P. Baum, K. Oberg, Irvin M. Modlin, and A. Frilling, Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology 110 (2020) 444-476.
[13] I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, and I.A. Cree, The 2019 WHO classification of tumours of the digestive system. Histopathology 76 (2019) 182-188.
[14] J.-H. Fan, Y.-Q. Zhang, S.-S. Shi, Y.-J. Chen, X.-H. Yuan, L.-M. Jiang, S.-M. Wang, L. Ma, Y.-T. He, C.-Y. Feng, X.-B. Sun, Q. Liu, K. Deloso, Y. Chi, and Y.-L. Qiao, A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget 8 (2017) 71699-71708.
[15] M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky, P. Brock, J. Chan, S. Das, P.V. Dickson, P. Fanta, T. Giordano, T.R. Halfdanarson, D. Halperin, J. He, A. Heaney, M.J. Heslin, F. Kandeel, A. Kardan, S.A. Khan, B.W. Kuvshinoff, C. Lieu, K. Miller, V.G. Pillarisetty, D. Reidy, S.A. Salgado, S. Shaheen, H.P. Soares, M.C. Soulen, J.R. Strosberg, C.R. Sussman, N.A. Trikalinos, N.A. Uboha, N. Vijayvergia, T. Wong, B. Lynn, and C. Hochstetler, Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19 (2021) 839-868.
[16] J. Franko, W. Feng, L. Yip, E. Genovese, and A.J. Moser, Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients. Journal of Gastrointestinal Surgery 14 (2010) 541-548.
[17] A.K. Stueven, A. Kayser, C. Wetz, H. Amthauer, A. Wree, F. Tacke, B. Wiedenmann, C. Roderburg, and H. Jann, Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences 20 (2019).
[18] A. Dasari, C. Shen, D. Halperin, B. Zhao, S. Zhou, Y. Xu, T. Shih, and J.C. Yao, Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology 3 (2017).
[19] J. Xu, L. Shen, C. Bai, W. Wang, J. Li, X. Yu, Z. Li, E. Li, X. Yuan, Y. Chi, Y. Yin, W. Lou, N. Xu, Y. Bai, T. Zhang, D. Xiu, X. Wang, Y. Yuan, J. Chen, S. Qin, R. Jia, M. Lu, Y. Cheng, Z. Zhou, J. Li, J. He, and W. Su, Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 21 (2020) 1489-1499.
[2] S. La Rosa, L. Boni, G. Finzi, D. Vigetti, N. Papanikolaou, S.M. Tenconi, G. Dionigi, M. Clerici, S. Garancini, and C. Capella, Ghrelin-Producing Well-Differentiated Neuroendocrine Tumor (Carcinoid) of Tailgut Cyst. Morphological, Immunohistochemical, Ultrastructural, and RT-PCR Study of a Case and Review of the Literature. Endocrine Pathology 21 (2010) 190-198.
[3] A. Lee, T.S. Suhardja, T.C. Nguyen, and W.M.-K. Teoh, Neuroendocrine tumour developing within a long-standing tailgut cyst: case report and review of the literature. Clinical Journal of Gastroenterology 12 (2019) 539-551.
[4] Z. Li, and M. Lu, Presacral Tumor: Insights From a Decade’s Experience of This Rare and Diverse Disease. Frontiers in Oncology 11 (2021).
[5] J. Ghosh, T. Eglinton, F.A. Frizelle, and A.J.M. Watson, Presacral tumours in adults. The Surgeon 5 (2007) 31-38.
[6] E. Canelles, J.V. Roig, M. Cantos, J. García Armengol, E. Barreiro, F.L. Villalba, M.D. Ruiz, and V. Pla, Tumores presacros. Análisis de nuestra experiencia en 20 casos tratados quirúrgicamente. Cirugía Española 85 (2009) 371-377.
[7] K. Kodera, S. Eto, N. Fukasawa, W. Kai, T. Matsumoto, T. Hirabayashi, H. Kawahara, and N. Omura, Laparoscopic resection of a neuroendocrine tumor that almost fully replaced tailgut cysts: a case report. Surgical Case Reports 6 (2020).
[8] D. Shi, G.-Q. Dong, K.-R. Shen, Y. Pan, S.-M. Wei, Y. Chen, and R.-S. Yu, Primary cystic and solid neuroendocrine tumor of the retroperitoneum. Medicine 100 (2021).
[9] V. Ulici, and J. Hart, Chordoma. Archives of Pathology & Laboratory Medicine 146 (2022) 386-395.
[10] E. Dekker, P.J. Tanis, J.L.A. Vleugels, P.M. Kasi, and M.B. Wallace, Colorectal cancer. The Lancet 394 (2019) 1467-1480.
[11] R. Syed, J.A. Bishop, and S.Z. Ali, Sacral and presacral lesions: Cytopathologic analysis and clinical correlates. Diagnostic Cytopathology 40 (2010) 7-13.
[12] Ashley K. Clift, M. Kidd, L. Bodei, C. Toumpanakis, Richard P. Baum, K. Oberg, Irvin M. Modlin, and A. Frilling, Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology 110 (2020) 444-476.
[13] I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, and I.A. Cree, The 2019 WHO classification of tumours of the digestive system. Histopathology 76 (2019) 182-188.
[14] J.-H. Fan, Y.-Q. Zhang, S.-S. Shi, Y.-J. Chen, X.-H. Yuan, L.-M. Jiang, S.-M. Wang, L. Ma, Y.-T. He, C.-Y. Feng, X.-B. Sun, Q. Liu, K. Deloso, Y. Chi, and Y.-L. Qiao, A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget 8 (2017) 71699-71708.
[15] M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky, P. Brock, J. Chan, S. Das, P.V. Dickson, P. Fanta, T. Giordano, T.R. Halfdanarson, D. Halperin, J. He, A. Heaney, M.J. Heslin, F. Kandeel, A. Kardan, S.A. Khan, B.W. Kuvshinoff, C. Lieu, K. Miller, V.G. Pillarisetty, D. Reidy, S.A. Salgado, S. Shaheen, H.P. Soares, M.C. Soulen, J.R. Strosberg, C.R. Sussman, N.A. Trikalinos, N.A. Uboha, N. Vijayvergia, T. Wong, B. Lynn, and C. Hochstetler, Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19 (2021) 839-868.
[16] J. Franko, W. Feng, L. Yip, E. Genovese, and A.J. Moser, Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients. Journal of Gastrointestinal Surgery 14 (2010) 541-548.
[17] A.K. Stueven, A. Kayser, C. Wetz, H. Amthauer, A. Wree, F. Tacke, B. Wiedenmann, C. Roderburg, and H. Jann, Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences 20 (2019).
[18] A. Dasari, C. Shen, D. Halperin, B. Zhao, S. Zhou, Y. Xu, T. Shih, and J.C. Yao, Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology 3 (2017).
[19] J. Xu, L. Shen, C. Bai, W. Wang, J. Li, X. Yu, Z. Li, E. Li, X. Yuan, Y. Chi, Y. Yin, W. Lou, N. Xu, Y. Bai, T. Zhang, D. Xiu, X. Wang, Y. Yuan, J. Chen, S. Qin, R. Jia, M. Lu, Y. Cheng, Z. Zhou, J. Li, J. He, and W. Su, Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 21 (2020) 1489-1499.
Copyright © 2024 Xinzhi Wang, Xiaofen Ma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License